Upcoming presentation will highlight encouraging top-line findings from a Phase 2 clinical trial assessing the effectiveness of BX211 in managing Diabetic Foot Osteomyelitis (DFO). The trial demonstrated positive results, indicating potential promise in treating this condition. The presentation will delve into the specifics of the successful outcomes from the trial, providing valuable insights into BX211's efficacy in addressing DFO.